Indinavir: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older editNewer edit →
David Canner (talk | contribs)
7,699 edits
No edit summary
David Canner (talk | contribs)
7,699 edits
No edit summary
Line 13: Line 13:
{| class="wikitable" border="1" width="52%" style="text-align:center"
{| class="wikitable" border="1" width="52%" style="text-align:center"
|-
|-
!  colspan="12" align="center"| HIV Protease Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]]<ref>PMID:20400409</ref><ref>Ferry et al, United States Patent US6147095, Pharmacia & Upjohn Company.</ref><ref>L. Veronese et al. Single-Dose Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor, in Subjects with Normal or Impaired Hepatic  Function. Antimicrob Agents Chemother. 2000 April; 44(4): 821–826.</ref><ref>J. Ford, et al. Intracellular and Plasma Pharmacokinetics of Saquinavir-Ritonavir, Administered at 1,600/100 Milligrams Once Daily in Human Immunodeficiency Virus-Infected Patients. Antimicrob Agents Chemother. 2004 July; 48(7): 2388–2393.</ref><ref>PMID:10620574</ref><ref>PMID:16086644</ref><ref>PMID:19131522</ref><ref>PMID: 10952482</ref><ref>PMID:16338276</ref><ref>PMID:19729375</ref><ref>PMID:12668574</ref>
!  colspan="12" align="center"| HIV Protease Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Translated|Pharmacokinetics]]<ref>PMID:20400409</ref><ref>Ferry et al, United States Patent US6147095, Pharmacia & Upjohn Company.</ref><ref>L. Veronese et al. Single-Dose Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor, in Subjects with Normal or Impaired Hepatic  Function. Antimicrob Agents Chemother. 2000 April; 44(4): 821–826.</ref><ref>J. Ford, et al. Intracellular and Plasma Pharmacokinetics of Saquinavir-Ritonavir, Administered at 1,600/100 Milligrams Once Daily in Human Immunodeficiency Virus-Infected Patients. Antimicrob Agents Chemother. 2004 July; 48(7): 2388–2393.</ref><ref>PMID:10620574</ref><ref>PMID:16086644</ref><ref>PMID:19131522</ref><ref>PMID: 10952482</ref><ref>PMID:16338276</ref><ref>PMID:19729375</ref><ref>PMID:12668574</ref><ref>PMID:17255144</ref>
|-
|-
! Parameter
! Parameter
Line 31: Line 31:
! ~3
! ~3
! 1.5
! 1.5
! Saquinavir
! 3.7
! .98
! .98
! Fosamprenavir
! Fosamprenavir
Line 37: Line 37:
! .5
! .5
! 2-4
! 2-4
! Nelfinavir
! 3.1
|-
|-
! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml)  
! [[Pharmaceutical_Drugs#Cmax|C<sub>max</sub>]] (ng/ml)  
Line 43: Line 43:
! 14600
! 14600
! 8100
! 8100
! 1540
! 2297
! 4901
! 4901
! Fosamprenavir
! Fosamprenavir
Line 49: Line 49:
! 2730
! 2730
! ~4393
! ~4393
! 4381
! 4701
|-
|-
! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%)
! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%)
Line 61: Line 61:
! Darunavir
! Darunavir
! 68
! 68
! Nelfinavir
! 20-80
|-
|-
! [[Pharmaceutical_Drugs#Protein_Binding|Protein Binding]] (%)
! [[Pharmaceutical_Drugs#Protein_Binding|Protein Binding]] (%)
Line 91: Line 91:
! 46500
! 46500
! 20900
! 20900
! 16200
! 13467
! 11999
! 11999
! Fosamprenavir
! Fosamprenavir
Line 97: Line 97:
! 4746
! 4746
! ~26045
! ~26045
! 27000
! 31906
|-
|-
! [[Pharmaceutical_Drugs#Clearance_.28Cl.29|Clearance]] (L/h)
! [[Pharmaceutical_Drugs#Clearance_.28Cl.29|Clearance]] (L/h)
Line 121: Line 121:
! 400
! 400
! 400
! 400
! 750
! 1250
|-
|-
! Metabolism
! Metabolism
Retrieved from "https://proteopedia.org/Indinavir"